Standard operating procedure
|
|
- Georgia Fitzgerald
- 8 years ago
- Views:
Transcription
1 Standard operating procedure Title: Review and revision of effective work instructions Status: PUBLIC Document no.: SOP/EMA/0034 Approver Effective date: 10-Jul-13 Name: Mario Benetti Name: Guido Rasi Review date: 10-Jul16 Signature: On file Signature: On file Supersedes: SOP/EMA/0034 (08-JUL-10) Date: 10-Jul-13 Date: 10-Jul-13 TrackWise record no.: Purpose To describe the procedure for reviewing and revising or withdrawing work instructions. 2. Scope This SOP applies to all lead authors involved in SOP/WIN drafting and to all Heads of Sector and Section Heads. 3. Responsibilities Each Head of Unit, Head of Sector and Section Head under the responsibility of the Executive Director must ensure that this procedure is adhered to within their own unit, sector or section. The responsibility for the execution of a particular part of this procedure is identified in the right-hand column of section Changes since last revision Revision of step 9 to adapt the instruction to the use of a MS Word SOP template instead of a template provided by TrackWise. Revision of step 12 to adapt the instruction with the use of MS Visio instead of MS Power Point to revise flowcharts, if required. Replacement of references to EDMS by DREAM and updating of instructions to reflect DREAM. 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom Telephone +44 (0) Facsimile +44 (0) info@ema.europa.eu Website An agency of the European Union European Medicines Agency, Reproduction is authorised provided the source is acknowledged.
2 5. Documents needed for this SOP WIN template in MS Word (provided solely by the ). Flow chart template in MS Visio (provided solely by the, if required). SOP_WIN transmission slip (provided solely by the ). 6. Related documents SOP/EMA/0013: Review and revision of effective standard operating procedures SOP/EMA/0033: Preparation and approval of new work instructions SOP/EMA/0037: Publication of, and training on standard operating procedures and work instructions WIN/EMA/0036: Creating flow charts for standard operating procedures and work instructions WIN/EMA/0053: Use of TrackWise software for SOP/WIN recording and tracking 7. Definitions DREAM: Document records electronic archive management system EMA bodies: Management Board, scientific committees, working parties, scientific advisory groups, etc. of the European Medicines Agency HoS/SH: Head of Sector/Section Head : Unit IQM co-ordinator or delegate ManualCo: IQM manual co-ordinator or delegate SOP: Standard operating procedure - Detailed, written instruction to achieve uniformity of the performance of a specific procedure; the instructions usually cover more than one task or area within the Agency, Unit or Sector TrackWise: Software for the tracking of processes and the creation and archiving of related records and associated documents. The SOP/WIN Management module is intended for the recording and tracking of SOPs and WIN WIN: Work instructions Detailed descriptions of how to perform and record tasks; they may be, for example, detailed written descriptions, flow charts, checklists, pictures, or combinations thereof WIN Review: To critically examine a WIN in due time before its review date to determine whether the written instructions/content and related forms/templates accurately describe and reflect the tasks followed in practice or not WIN Revision: To modify a WIN and related forms/templates to accurately describe the tasks followed in practice as a result of a review or a change in the tasks at any time before the review date SOP/EMA/0034, 10-Jul-13 Page 2/7
3 8. Process map(s)/ flow chart(s) START 1. Is WIN due for review or requires revision? For review For revision 2. Prepare list of Unit WIN. Forward to HoS/SH/ interested persons 3. Review list in Unit/ Sectors/Sections 4. Approve review of WIN Reconfirm/appoint lead author, review team & approver Determine need for consultation Define publication status 5. Review WIN and related forms/templates 6. Inform Unit 7. Update WIN status. Create TrackWise record (WIN/EMA/0053). Send to lead author 8. Is WIN obsolete? Yes 9. Inform No To Is revision required? No 11. Finalise WIN Yes 12. Revise WIN and forms/templates To Inform To 14. SOP/EMA/0034, 10-Jul-13 Page 3/7
4 From Go to SOP/EMA/0013 Yes 14. Is consultation required? No 16. Carry out QC check 17. Implement corrections, if required 18. Update WIN status Print hard copy Update TrackWise record (WIN/EMA/0053) Generate transmission slip Categorise in activity area/type From Sign WIN (lead author) 20. Read and sign WIN (approver) 21. Go to SOP/EMA/0037 From 9. END SOP/EMA/0034, 10-Jul-13 Page 4/7
5 9. Procedure Step Action Responsibility 1 For effective WIN due for review, go to step 2. If an effective WIN needs to be reviewed well before its review date due to a change in the procedure, go to step 4. 2 On a regular basis as determined by each Unit, generate a list of WIN falling under the responsibility of the respective Unit that are due for review within the next 3 months or that have expired and are pending review. HoS/SH/Lead author Forward list to HoS, SH and other concerned persons in the respective Unit. 3 Review the list in the respective Unit/Sectors/Sections and prioritise review of WIN. 4 Approve review of WIN. HoS/SH HoS/SH Re-confirm or assign lead author of WIN. Appoint/re-appoint review team having a good knowledge of the tasks involved. If cross-section/sector/unit representation is necessary, consult with other SH/HoS/HoU to appoint team members. Re-assign consultation status, publication status and approver (refer to SOP/EMA/0033). 5 Inform by of WIN to be reviewed, need for consultation or otherwise, publication status, and lead author, review team and approver names. 6 Update status of WIN (refer to WIN/EMA/0035). Check in to DREAM. Create new record in TrackWise (refer to WIN/EMA/0053). When completed, send to lead author with the link to the WIN-specific folder in DREAM. 7 Review the WIN and related forms/templates, if applicable, to evaluate the need for a revision or otherwise. 8 If the procedure described in the WIN is obsolete, go to step 9. If the procedure described in the WIN is still valid, go to step Inform that the WIN is obsolete and should be withdrawn. Go to step 21. SOP/EMA/0034, 10-Jul-13 Page 5/7
6 Step Action Responsibility 10 If the procedure has not changed in any way and the WIN does not require revision, go to step 11. If the WIN needs to be revised, go to step Update the section Changes since last revision by replacing existing text with WIN reviewed and reissued without any changes. Inform that WIN can be re-issued without changes. Go to step Revise the WIN using the MS Word document provided by the. Update the section Changes since last revision by briefly listing the changes that have been made and are included in the revised version of the WIN. Changes from previous versions recorded under the heading should be replaced by the most recent changes. If extensive changes are made, type Extensive revision to rewrite WIN. Use the same approach described in SOP/EMA/0033 to update the content of the WIN. Verify if any related documents or forms, templates, etc need to be revised concurrently. Ensure that all functions identified as responsible for specific actions described in the WIN have been consulted and engaged in the review of the WIN. If the WIN contains a flow chart, revise the MS Visio version available in the same WIN-specific folder. Paste the updated flow chart as a picture (enhanced metafile) in the SOP (refer to WIN/EMA/0036). Save all versions of the revised WIN in the WIN-specific folder provided. In case of difficulty with any part of this step, seek assistance of the. 13 When revision is completed, inform and discuss the required length of consultation. Note: For a revised WIN, the length of consultation is 2 weeks; If other EMA bodies need to be consulted the length of consultation may be longer than the standard 2 weeks (there is no maximum length in this case). 14 If consultation has been requested, go to step 15. If the WIN is very specific to tasks undertaken by a restricted group of persons no cross Agency consultation is required. Go to step Follow consultation procedure detailed in SOP/EMA/0013. SOP/EMA/0034, 10-Jul-13 Page 6/7
7 Step Action Responsibility 16 Carry out quality check (use checklist in WIN/EMA/0053) and request lead author to make corrections, if required. 17 Make necessary corrections to WIN and forms/templates, if required. 18 Update status of WIN to agreed publication status as informed in step 4. Print hard copy. Check in to DREAM. Open the WIN record in TrackWise, document quality check and update required fields (refer to WIN/EMA/0053). Prepare the SOP_WIN transmission slip. (Re-)Categorise the WIN in the relevant activity area and type for web publication, and document in the transmission slip. Forward WIN and transmission slip to lead author. 19 Sign WIN and transmission slip. Forward to approver. 20 Read WIN and sign WIN and transmission slip. Approver Forward to. 21 Refer to SOP/EMA/ Records Electronic records of WIN are generated and saved in TrackWise. Electronic documents are filed in DREAM under: Cabinets/06. Corporate governance/06.2 Integrated Management System/2. IMS Manual/5. SOPs and WINs SOP/EMA/0034, 10-Jul-13 Page 7/7
Standard operating procedure
Standard operating procedure Title: Review and revision of effective standard operating procedures Status: PUBLIC Document no.: SOP/EMA/0013 Approver Effective date: 10-Jul-13 Name: Mario Benetti Name:
More informationStandard operating procedure
Standard operating procedure Title: Audit programmes and internal audits conducted by the Audit Advisory Function Status: PUBLIC Document no.: SOP/EMA/0025 Lead author Approver Effective date: 29/07/2014
More informationWork instructions. 1. Changes since last revision. 2. Records. 3. Instructions. Title: How to create reports from scientific memory database (SMD)
Work instructions Title: How to create reports from scientific memory database (SMD) Applies to: Clinical and Non-Clinical Compliance Section Status: PUBLIC Document no.: WIN/INSP/2040 Lead Author Approver
More informationStandard operating procedure
Standard operating procedure Title: How to conduct a procurement procedure Status: PUBLIC Document no.: SOP/EMA/0121 Lead author Approver Effective date: 04.09.14 Name: Caroline Maignen Name: Stefano Marino
More informationStandard operating procedure
Standard operating procedure Title: Steps involved in outsourcing of services Status: PUBLIC Document no.: SOP/EMA/0083 Lead author Approver Effective date: 18-12-2014 Name: Caroline Maignen Name: Stefano
More informationStandard operating procedure
Standard operating procedure Title: Evaluation procedure for eligibility of patients', consumers' and healthcare professionals organisations Status: Public Document no.: SOP/H/3390 Lead author Approver
More informationAll the steps detailed in this WIN are carried out by the assistant in the Sampling and Testing Team in the MQC Section.
Work instructions Title: Sampling and testing of centrally authorised products - update of spreadsheet for the identification of the products to be tested on the basis of a risk assessment Applies to:
More informationEU Clinical Trials Register. www.clinicaltrialsregister.eu. An agency of the European Union
EU Clinical Trials Register www.clinicaltrialsregister.eu An agency of the European Union The EU Clinical Trials Register provides public access to information from the European Union (EU) clinical trial
More informationStandard operating procedure
Standard operating procedure Title: Eligibility to the centralised procedure for medicinal products for human use Status: PUBLIC Document no.: SOP/H/3462 Lead author Approver Effective date: 05-FEB-16
More informationStandard operating procedure
Standard operating procedure Title: Handling invoice payment within deadline of 30 days (Standard Payments) Status: PUBLIC Document no.: SOP/EMA/0135 Lead author Approver Effective date: 18-FEB-2015 ame:
More informationReflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials
1 2 3 5 August 2011 EMA/INS/GCP/600788/2011 Compliance and Inspection 4 5 6 7 Reflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials
More informationQuestions and answers on post approval change management protocols
27 October 2010 EMA/CHMP/CVMP/QWP/586330/2010 Questions and answers on post approval change management protocols Draft Draft Agreed by QWP September 2010 Adoption by CHMP for release for consultation 23
More informationEnd of consultation (deadline for comments) 14 October 2009. Adoption by Committee for advanced therapies 15 October 2010
15 October 2010 EMA/CAT/418458/2008/corr. Committee for advanced therapies (CAT) Procedural advice on the certification of quality and nonclinical data for small and medium sized enterprises developing
More informationGuidance for the format and content of the protocol of non-interventional post-authorisation safety studies
26 September 2012 EMA/623947/2012 Patient Health Protection Guidance for the format and content of the protocol of non-interventional post-authorisation Introduction From 10 January 2013, marketing authorisation
More informationEMA esignature capabilities: frequently asked questions relating to practical and technical aspects of the implementation
August 2013 EMA/264709/2013 EMA esignature capabilities: frequently asked questions relating to practical and technical aspects of the implementation This question and answer document aims to address the
More informationAdoption by GCP Inspectors Working Group for consultation 14 June 2011. End of consultation (deadline for comments) 15 February 2012
10 December 2013 EMA/INS/GCP/600788/2011 Compliance and Inspection Reflection paper on the use of interactive response technologies (interactive voice/web response systems) in clinical trials, with particular
More informationQuestions and answers on post approval change management protocols
30 March 2012 EMA/CHMP/CVMP/QWP/586330/2010 Committee for Medicinal Products for Human Use (CHMP) Questions and answers on post approval change management protocols Draft agreed by CHMP / CVMP Quality
More informationReflection paper on expectations for electronic source data and data transcribed to electronic data collection tools in clinical trials
09 June 2010 EMA/INS/GCP/454280/2010 GCP Inspectors Working Group (GCP IWG) Reflection paper on expectations for electronic source data and data transcribed to electronic data collection tools in clinical
More informationQuestions and answers relating to Open Procedure EMA 2012-37-ED Online Strategy and Interface Design
27 June 2013 EMA/352562/2013 Questions and answers relating to Open Procedure EMA 2012-37-ED Online Strategy and Interface Design Table of contents Questions and answers... 2 Document history... 6 7 Westferry
More informationQuestions and answers relating to Restricted tender procedure EMA/2012/19/IS Provision of Security Consultancy Services
30 October 2012 EMA/702274/2012 Questions and answers relating to Restricted tender procedure EMA/2012/19/IS Provision of Security Consultancy Services Table of contents Questions and answers... 2 Document
More informationWork instructions. 1. Changes since last revision. 2. Records. 3. Instructions EXPLANATORY NOTES
Work instructions Title: Calculation of fees for GMP and product related inspections Applies to: P-CI-MQC staff Status: PUBLIC Document no.: WIN/INSP/2043 Lead Author Approver Effective Date: 13-APR-12
More informationCompilation of Community Procedures on Inspections and Exchange of Information
EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE- GENERAL Public Health and Risk Assessment Pharmaceuticals 27 June 2013 EMA/385898/2013 Rev 16 Compliance and Inspection Compilation of Community
More informationDistant/virtual pharmacovigilance inspections of MAHs during a crisis situation- Points to consider
18 January 2013 EMA/INS/119905/2012 Compliance and Inspection Distant/virtual pharmacovigilance inspections of MAHs during a crisis situation- Points This document is intended to provide guidance on the
More informationAnnex VI Service Level Agreement for Medical Service Provider
Annex VI Service Level Agreement for Medical Service Provider The term medical service provider referred to in this document is the contractor with which the Agencies i.e. EMA, EBA and CEPOL have signed
More informationStandard Operating Procedure
Standard Operating Procedure Title: Production and Control of Standard Operating Procedures Purpose The purpose of this SOP is to describe the procedure to be followed to ensure that SOPs are produced
More informationPROCEDURE FOR PREPARING GCP INSPECTIONS REQUESTED BY THE EMEA. GCP Inspectors Working Group
European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197228/2005 Procedure no.: INS/GCP/2 PROCEDURE FOR PREPARING GCP INSPECTIONS REQUESTED BY THE EMEA GCP Inspectors Working Group
More informationXML Conversion Utility User Awareness
8 March 2011 Topics Prerequisites What you do Know Issues Prerequisites: Note: EudraCT Version 8 has a more comprehensive set of field validation to ensure data completeness and consistency that EudraCT
More informationReflection paper for laboratories that perform the analysis or evaluation of clinical trial samples
28 February 2012 EMA/INS/GCP/532137/2010 GCP Inspectors Working Group Reflection paper for laboratories that perform the analysis or evaluation of clinical trial Draft agreed by GCP Inspectors Working
More informationQuestions and answers relating to Open Tender EMA/2012/21/IS
12 December 2012 EMA/748793/2012 Table of contents Questions and answers... 2 Document history... 7 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom Telephone +44 (0)20 7418 8400 Facsimile
More informationSubmission of comments on 'Policy 0070 on publication and access to clinical-trial data'
EMA/240810/2013 Submission of comments on 'Policy 0070 on publication and access to clinical-trial data' s from: Name and affiliation PHARMIG - Association of the Austrian pharmaceutical industry Please
More informationRegulatory approval routes in the European System for Medicinal Products
Regulatory approval routes in the European System for Medicinal Products Cardiovascular Combination Pharmacotherapy Global Summit, Melbourne, 8 th May 2014 Presented by: Kevin Blake Human Medicines Research
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 17 July 2006 Doc. Ref. EMEA/419127/05 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PROCEDURE
More informationEuropean Medicines Agency decision
EMA/650134/2010 European Medicines Agency decision P/202/2010 of 27 October 2010 on the acceptance of a modification of an agreed paediatric investigation plan for propranolol hydrochloride, (EMEA-000511-PIP01-08-M02)
More informationReflection paper on GCP compliance in relation to trial master files (paper and/or electronic) for management, audit and inspection of clinical trials
1 2 3 15 June 2015 EMA/INS/GCP/636736/2012 Good Clinical Practice Inspectors Working Group (GCP IWG) 4 5 6 7 Reflection paper on GCP compliance in relation to trial master files (paper and/or electronic)
More informationGuideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)
22 May 2014 EMA/CHMP/BWP/247713/2012 Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:
More informationDraft Agreed by Pharmacokinetics Working Party January 2011. End of consultation (deadline for comments) 31 May 2011
1 2 3 17 February 2011 EMA/CHMP/600958/2010 Committee of Medicines for Human Use (CHMP) 4 5 6 7 8 Appendix IV of the Guideline on the Investigation on Bioequivalence (CPMP/EWP/QWP/1401/98 Rev.1): Presentation
More informationAdoption by CHMP for release for consultation November 2010. End of consultation (deadline for comments) 31 March 2011
1 2 3 November 2010 EMA/759784/2010 Committee for Medicinal Products for Human Use 4 5 6 7 Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and
More informationGCP INSPECTORS WORKING GROUP <DRAFT> REFLECTION PAPER ON EXPECTATIONS FOR ELECTRONIC SOURCE DOCUMENTS USED IN CLINICAL TRIALS
European Medicines Agency London, 17 October 2007 Doc. Ref. EMEA/505620/2007 GCP INSPECTORS WORKING GROUP REFLECTION PAPER ON EXPECTATIONS FOR ELECTRONIC SOURCE DOCUMENTS USED IN CLINICAL TRIALS
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON DATA MONITORING COMMITTEES
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 27 July 2005 Doc. Ref. EMEA/CHMP/EWP/5872/03 Corr COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 20 February 2012 EMA/541760/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration
More informationGuideline on Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs)
London, 21 April 2009 Doc. Ref. EMA/13432/2009 Committee for Medicinal Products for Human Use (CHMP) Guideline on Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)
European Medicines Agency Veterinary Medicines and Inspections London, 15 April 2005 EMEA/CVMP/134/02 Rev 1 CPMP/QWP/227/02 Rev 1 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY
More informationReflection paper on clinical aspects related to tissue engineered products
1 2 3 19 March 2012 EMA/CAT/CPWP/573420/2009 Committee for Advanced Therapies (CAT) 4 5 6 Reflection paper on clinical aspects related to tissue engineered products Draft Draft agreed by CPWP 7 October
More informationOne-year report on human medicines pharmacovigilance tasks of the European Medicines Agency
8 April 2014 EMA/171322/2014 Pharmacovigilance Department One-year report on human medicines pharmacovigilance tasks of the European Medicines Agency Reporting period: 2 July 2012 to 1 July 2013 7 Westferry
More informationTechnical specifications for open invitation to tender
7 June 2013 EMA/680395/2012 No. EMA 2012-37-ED: Online strategy and interface design Table of contents 1. Title of the invitation to tender... 3 2. Objectives and context of the invitation to tender...
More informationSubmission of comments on 'Policy 0070 on publication and access to clinical-trial data'
EMA/240810/2013 Submission of comments on 'Policy 0070 on publication and access to clinical-trial data' s from: Name and affiliation For the Austrian Medicines & Medical Devices Agency (AGES), Austria,
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/044/99-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT
More informationGuideline on stability testing for applications for variations to a marketing authorisation
21 March 2014 EMA/CHMP/CVMP/QWP/441071/2011- Rev.2 Committee for Medicinal Products for Human Use (CHMP)/ Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on stability testing for applications
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: SOP number: SOP category: Document Control GE-003 General SOP history Version number: 01 Version date: 1 March 2013 Effective
More informationHow to search the EU Clinical Trials Register
28 April 2014 Information and Communications Technology Contents Contents... 1 1. Searching the EU Clinical Trials Register... 1 1.1. Basic search... 2 1.2. Search for multiple words (AND operator)...
More informationMarie-Claire Rickard, GCP & Governance Manager Rachel Fay, GCP & Governance Manager Elizabeth Clough, R&D Operations Manager
Standard Operating Procedures (SOP) for: Monitoring SOP 28 Version 7.0 Number: Number: Effective Date: 29 th November 2015 Review Date: 6 th January 2017 Author: Reviewer: Reviewer: Authorisation: Name
More informationQuick Response (QR) codes in the labelling and package leaflet of centrally authorised 1 medicinal products
22 July 2015 EMA/493897/2015 Human Medicines Evaluation Division Quick Response (QR) codes in the labelling and package leaflet of centrally authorised 1 medicinal General principles of acceptability and
More informationWHS Document Management Procedure
1. Overview The purpose of this procedure is to provide minimum standards for how Wudinna District Council will maintain its WHS Management System documentation so that documents are drafted, maintained,
More informationDraft agreed by Pharmacokinetics Working Party January 2011. Adoption by CHMP for release for consultation 17 February 2011
17 November 2011 EMA/CHMP/600958/2010/Corr.* Committee of Medicines for Human Use (CHMP) Appendix IV of the Guideline on the Investigation on Bioequivalence (CPMP/EWP/QWP/1401/98 Rev.1): Presentation of
More informationBEST PRACTICE GUIDE for Handling of Periodic Safety Update Reports
EMEA/CMDv/408477/2007 12 March 2009 BEST PRACTICE GUIDE for Handling of Periodic Safety Update Reports Edition number : 00 Edition date: 12 March 2009 Implementation date : 27 March 2009 CMD(v) Secretariat:
More informationIn non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes:
EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human
More informationResources Based, Manufacturing and Consumer Goods Industries Chemicals Industry
EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Resources Based, Manufacturing and Consumer Goods Industries Chemicals Industry Version March 2015 QUESTIONS
More informationGuideline on Process Validation
1 2 3 4 29 March 2012 EMA/CHMP/CVMP/QWP/70278/2012-Rev1 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) 5 6 Draft Draft Agreed by CHMP /
More informationDCO No. Released By: Effective Date Document No. Rev.
1.0 Purpose The Engineering Change Order is a tool utilized by the Safety that records and tracks the design and review process for engineering jobs. 2.0 Scope All new designs and modifications to existing
More informationSevere rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate.
EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human
More informationSP007 - Procedure for the Control of Documents & Data
1.1 SCOPE: SP007 - Procedure for the Control of Documents & Data In conformance with the requirements of ISO 9001:2008, document, data control is essential for the overall efficiency and quality of London
More informationThe Clinical Trials Regulation EU No 536/2014: and Phase I trials
The Clinical Trials Regulation EU No 536/2014: and Phase I trials EUFEMED, Brussels, 20 May 2015 Presented by Fergus Sweeney Head, Inspections and Human Medicines Pharmacovigilance An agency of the European
More informationEnergy Management. System Short Guides. A Supplement to the EPA. Guidebook for Drinking Water and Wastewater Utilities (2008)
Energy Management System Short Guides A Supplement to the EPA Energy Management Guidebook for Drinking Water and Wastewater Utilities (2008) PREPARED BY GLOBAL ENVIRONMENT & TECHNOLOGY FOUNDATION (A 501(C)(3)
More informationWorkshop on multiple sclerosis
7 October 2013 EMA/263897/2013 Scientific and Regulatory Management Department Final programme 17 October 2013 European Medicines Agency, London, United Kingdom Room 2A 7 Westferry Circus Canary Wharf
More informationQuestions & answers on signal management
23 October 2015 EMA/261758/2013 Inspections and Human Medicines Pharmacovigilance Division This document addresses a number of questions which stakeholders, in particular marketing authorisation holders
More informationCompilation of Community Procedures on Inspections and Exchange of Information
EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE- GENERAL Public Health and Risk Assessment Pharmaceuticals 3 October 2014 EMA/572454/2014 Rev 17 Compliance and Inspection Compilation of Community
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/541760/2011 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration with Member
More informationIMS-ST-1.04 Document and Record Management. Prepared By: Jacqueline Raynes Print Date: 20/08/13 Version No: V01 Reviewed By: Jeff Innes
Integrated Management Standard 1.04 Document and Record Management Contents 1 Purpose... 2 2 Scope... 2 3 Standard... 2 3.1 OTML Documentation Overview... 2 3.2 Integrated Management System Documentation...
More informationDistrict Council of Cleve
1. Overview The purpose of this procedure is to provide minimum standards for how the District Council of Cleve will maintain its WHS management system documentation so that documents are drafted, maintained,
More informationReflection Paper on Medicinal Product Supply Shortages Caused by Manufacturing/GMP Compliance Problems
14 September 2012 /590745/2012 Patient Health Protection Reflection Paper on Medicinal Product Supply Shortages Caused by Manufacturing/GMP 1. Introduction Ensuring the security and Good Manufacturing
More informationCompilation of individual product-specific guidance on demonstration of bioequivalence
17 December 2014 EMA/CHMP/736403/2014 Committee for Medicinal Products for Human Use (CHMP) Compilation of individual product-specific guidance on demonstration of bioequivalence Initial batch of individual
More informationJoint Account Application Form
Joint Account Application Form Capital Index (UK) Limited is authorised and regulated by the Financial Conduct Authority (registration number 709693). If you have any questions regarding the completion
More informationArchiving of Clinical Trial Data and Essential Documentation JCTO/CT/SOP 4.0. Joint Clinical Trials Office. Stuart Hatcher, JCTO Archivist
Archiving of Clinical Trial Data and Essential Documentation Policy Details Document Type Standard Operating Procedure Document name Change History Date Version Number JCTO/CT/SOP 4.0 Version Final v 2.0-09/11/2010
More informationThe EU portal and database
The EU portal and database ECPC General Assembly - 20 June 2015 Presented by Laura Pioppo Clinical and Non-clinical Compliance Service An agency of the European Union Table of contents Legal basis CT programme
More informationAir Traffic Service Providers Entry Control Procedures Manual 2. Approval Procedures for ATS Providers
2.1 Approval Procedures for ATS Providers Flowchart POTENTIAL ATS PROVIDER Contacts CASA re process in provision of ATS CASA TO DESPATCH INFORMATION PACK CONTAINING : Covering letter outlining application
More informationEU PAS Register Guide
29 March 2016 EMA/613603/2012 (currently ENCePP E-Register of Studies) The EU PAS Register is temporarily hosted on the ENCePP website www.encepp.eu 1. Introduction... 2 2. ENCePP E-Register as a temporary
More informationRFM Procedure 8: Document Control and Record Management Alaska Responsible Fisheries Management (RFM) Certification Program 17065
RFM Procedure 8: Document Control and Record Alaska Responsible Fisheries (RFM) Certification Program 17065 RFM Procedure 8: Document Control and Record, Version 3, Nov. 2015 1 1. Purpose This procedure
More informationIT Operations User Access Management Policies
1. Approval and Authorisation Completion of the following signature blocks signifies the review and approval of this Process (signed copy held in safe) Name Job Title Signature Date Authored by:-
More informationStrategy and pilot phase for patient registries
Strategy and pilot phase for patient registries Draft still under discussion Industry Stakeholder Platform - Operation of EU Pharmacovigilance Legislation 12 January 2015 Xavier Kurz, Head of Monitoring
More informationGuideline on good pharmacovigilance practices (GVP)
9 April 2013 EMA/816573/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module II Pharmacovigilance system master file (Rev 1) Draft of first version finalised by the Agency in collaboration
More informationRules for the certification of event sustainability management system
Rules for the certification of event sustainability management system In force from 10/09/2014 RINA Services S.p.A. Via Corsica, 12 16128 Genova Tel. +39 010 53851 Fax +39 010 5351000 E-MAIL: info@rina.org,
More informationDisability ACT. Policy Management Framework
Disability ACT Policy Management Framework OCT 2012 Disability ACT Policy Management Framework Version October 2012 Page 1 of 19 1. Context... 3 1.1 Purpose... 3 1.2 Scope... 3 1.3 Background... 3 1.4
More informationDate : Date of start of procedure: Authorisation/ positive opinion :
Substantial Amendment Notification Form (Cf. Section 3.7.b of the Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use,
More information5.3.1 Document Control Faculty/Division/School/Branch
Human Resources HSW Handbook 5.3.1 Document Control Faculty/Division/School/Branch Information Sheet Purpose The purpose of this Information sheet is to clarify how document control should be applied to
More informationICH guideline Q8, Q9 and Q10 - questions and answers volume 4
December 2010 EMA/CHMP/ICH/265145/ Committee for medicinal products for human use (CHMP) ICH guideline Q8, Q9 and Q10 - questions and answers volume 4 Step 5 Transmission to CHMP for information December
More informationQRD recommendations on pack design and labelling for centrally authorised non-prescription human medicinal products
1 2 3 10 March 2011 Quality Review Documents (QRD) 4 5 6 7 QRD recommendations on pack design and labelling for centrally authorised non-prescription human medicinal products Draft Draft Agreed by Quality
More informationComputer System Validation for Clinical Trials:
Computer System Validation for Clinical Trials: Framework Standard Operating Procedure (F-SOP) Author: Tim Cross Version History: 0.1di DRAFT 24-April-2013 0.2 DRAFT 12-June-2013 Current Version: 1.0 17-June-2013
More informationProcurement, Contracting and Contract Management Policy
Procurement, Contracting and Contract Management Policy Corporate policy 8.4 Responsible Officer: Group Manager Accounting and Taxation Policy Custodian: Chief Finance Officer Division: Finance and Resources
More informationRules for the certification of asset management systems
Rules for the certification of asset management systems In force from 8/09/2014 RINA Services S.p.A. Via Corsica, 12 16128 Genova Tel. +39 010 53851 Fax +39 010 5351000 E-MAIL: info@rina.org, web: www.rina.org
More informationWalton Centre. Document Control. Document History Date Version Author Changes 01/10/2004 1.0 A Cobain
Page 1 Walton Centre Document Control Document History Date Version Author Changes 01/10/2004 1.0 A Cobain Page 2 Table of Contents Section Contents 1 Introduction 2 Responsibilities Within This Document
More informationGuidance for Member States on Audit of Accounts
EGESIF_15_0016-02 final 05/02/2016 EUROPEAN COMMISSION European Structural and Investment Funds Guidance for Member States on Audit of Accounts DISCLAIMER: This is a document prepared by the Commission
More informationMonitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency
28 August 2015 EMA/386784/2015 Inspections and Human Medicines Pharmacovigilance Division Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS
European Medicines Agency Evaluation of Medicines for Human Use CHMP/437/04 London, 30 October 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS
More informationTable Of Contents. DOCUMENT CONTROL EHS-XX Page 1 of 7. Environment, Health & Safety
DOCUMENT CONTROL EHS-XX Page 1 of 7 Table Of Contents 1. Purpose & Scope... 2 2. Definitions... 2 2.1. Controlled Document/Procedure... 2 2.2. Amendment/Revision.... 2 2.3. Interim Instruction.... 2 2.4.
More informationPOST-AUTHORISATION GUIDANCE. Human Medicinal Products
European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use London, 23 February 2006 Doc. Ref. EMEA/180079/2005 POST-AUTHORISATION GUIDANCE Human Medicinal Products QUESTIONS AND
More informationVICTORIAN GOVERNMENT DEPARTMENT ENVIRONMENTAL MANAGEMENT SYSTEM MODEL MANUAL
MODEL FINAL VERSION 1, MARCH 2003 ACKNOWLEDGMENTS This Manual is based on Environment Australia s Model EMS 1 and has been adapted for use by Victorian Government agencies by Richard Oliver International.
More informationwww.ffcu4u.com SWITCH KIT The Quick and Easy Way to Make the Switch Of Your Financial Accounts BENEFITS:
www.ffcu4u.com SWITCH KIT The Quick and Easy Way to Make the Switch Of Your Financial Accounts BENEFITS: 24,000 Fee Free ATM s Free Debit Cards Free CU24 Internet Banking Free Online Bill Pay Free Call
More informationEMA/AD/350: Scientific Administrator, Quality of Medicines, Human Medicines Development and Evaluation Unit (AD6)
12 June 2013 EMA/270563/2013 Administration EMA/AD/350: Scientific Administrator, Quality of Medicines, Human Medicines Development and Evaluation Unit (AD6) The Agency is looking to recruit a competent
More informationThe European Medicines Agency s Integrated Quality Management System
European Medicines Agency POLICY/0001 EMEA/MB/355781/2007Rev.1 The European Medicines Agency s Integrated Quality Management System 1. Introduction and purpose This policy describes the purpose and structure
More informationWHS DOCUMENT MANAGEMENT PROCEDURE
1. OVERVIEW The purpose of this procedure is to provide minimum standards for how The Flinders Ranges Council will maintain its WHS management system documentation so that documents are drafted, maintained,
More information